Clinical and molecular diagnosis of non-phosphomannomutase 2 N-linked congenital disorders of glycosylation in Spain.
Celia MedranoAna VegaRosa NavarreteM Jesús EcayRocío CalvoSamuel Ignacio PascualMónica Ruiz-PonsLaura ToledoInmaculada García-JiménezIgnacio ArroyoAndrea CampoM Luz CouceM Rosario Domingo-JiménezM Teresa García-SilvaLuis González-Gutiérrez-SolanaLoreto HierroElena Martín-HernándezMercedes Martínez-PardoSusana RoldánMiguel TomásJose C CabreraFrancisco Mártinez-BugalloLucía Martín-ViotaIsidro Vitoria-MiñanaDirk J LefeberM Luisa GirósMercedes Serrano GimareMagdalena UgarteBelén PérezCelia Pérez-CerdáPublished in: Clinical genetics (2019)
The congenital disorders of glycosylation (CDG) are defects in glycoprotein and glycolipid glycan synthesis and attachment. They affect multiple organ/systems, but non-specific symptoms render the diagnosis of the different CDG very challenging. Phosphomannomutase 2 (PMM2)-CDG is the most common CDG, but advances in genetic analysis have shown others to occur more commonly than previously thought. The present work reports the clinical and mutational spectrum of 25 non-PMM2 CDG patients. The most common clinical symptoms were hypotonia (80%), motor or psychomotor disability (80%) and craniofacial dysmorphism (76%). Based on their serum transferrin isoform profile, 18 were classified as CDG-I and 7 as CDG-II. Pathogenic variations were found in 16 genes (ALG1, ALG6, ATP6V0A2, B4GALT1, CCDC115, COG7, DOLK, DPAGT1, DPM1, GFPT1, MPI, PGM1, RFT1, SLC35A2, SRD5A3, and SSR4). Overall, 27 variants were identified, 12 of which are novel. The results highlight the importance of combining genetic and biochemical analyses for the early diagnosis of this heterogeneous group of disorders.